Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdNRGM
- Development stage
- Unknown
- Lead developer
- Zensun
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intracoronary
01
Overview
AdNRGM is an investigational gene therapy consisting of a recombinant adenoviral vector (typically serotype 5) encoding the epidermal growth factor (EGF)-like domain of human neuregulin-1 (NRG1). Developed by Zensun (Shanghai) Sci & Tech, it is designed for the treatment of chronic heart failure. The mechanism involves the local expression of NRG1, which binds to and activates ErbB4 receptors on cardiomyocytes, subsequently inducing heterodimerization with ErbB2. This activation triggers downstream signaling pathways, including PI3K/Akt and MAPK, which promote cardiomyocyte survival, improve sarcomere organization, and enhance cardiac contractility. By delivering the NRG1 gene directly to the cardiac environment, AdNRGM aims to provide a sustained therapeutic effect and overcome the short half-life limitations associated with recombinant protein administration.
- Other names
- Adenoviral Neuregulin-1Ad-NRG1Ad-NRG-1Ad-NRG 1
02
Targets
ERBB4 (Erb-b2 receptor tyrosine kinase 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on AdNRGM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdNRGM.